Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tutogen Medical, Inc. (OTCBB: TTGN) -- Ignore unavailable to you. Want to Upgrade?

To: leigh aulper who wrote (34)	10/5/2000 8:10:11 AM
From: leigh aulper	Respond to of 56

Tutogen Medical to Receive Up to $1,000,000 From Sulzer Medica's Calcitek Inc. for License, Development and Distribution Agreements CLIFTON, N.J.--(BUSINESS WIRE)--Oct. 5, 2000--Tutogen Medical, Inc. (AMEX: TTG) today announced that it has signed three agreements with Sulzer Calcitek Inc., a market leader for dental products. The first agreement, the Processed Tissue Development and License Agreement, engages both companies in the development of processed tissues for dental surgery. This agreement's initial term is for 10 years, and Tutogen has received $200,000 for its participation. The second agreement, the U.S. Service Agreement, grants Sulzer the exclusive right to distribute Tutoplast Processed Allograft bone tissue worldwide with the main focus on the U.S.A. This agreement is for an initial term of 10 years, and has been granted to Sulzer for $200,000. The third agreement, the Xenograft Distribution Agreement, provides Sulzer with the exclusive right to distribute Tutogen's xenograft bone tissue worldwide for dental applications. This agreement is for an initial term of 10 years also. In exchange for this right of distribution, Sulzer has agreed to pay Tutogen $200,000 on the execution of this agreement; $200,000 following Sulzer's first delivery of product in Western Europe, and $200,000 upon issuance of an FDA 510(k) approval for commercial sales of the product in the U.S. Manfred Kruger, President and CEO of Tutogen commented, "These agreements form a crucial part of our business plan whose goal is for Tutogen to become a world leader in the Bioimplant Industry. Sulzer Medica's continued focus to develop and bring biotechnology products to the market will greatly enhance and accelerate the achievement of Tutogen's goals." Steven Hansen, President of Sulzer Calcitek Inc. commented; "The opportunities available now and inthe future for the adoption of Bioimplants as the material of choice for bone repair are great. Our choice of partnering with`Tutogen reflects our view that their patented Tutoplast(R) process for xenografts and allografts is the safest and best available." Tutogen Medical, Inc. utilizes its proprietary Tutoplast(R) process of tissue preservation and viral inactivation, to manufacture bioimplants for dental, neurosurgical, orthopedic, reconstructive and general surgical indications. The Company's Tutoplast(R) products are distributed worldwide by the Mentor Corporation (MNTR), Sulzer Medica (SM) and IOP, Inc., and through subsidiaries in the U.S. and Germany as well as through Tutogen's own distribution network worldwide.